Mumbai: Mumbai-based drug maker Piramal Healthcare Ltd on Wednesday said that it has obtained an ex parte injunction from the Bombay high court against four local drug companies for infringing its trade mark for arthritic pain reliever Esgipyrin.
The companies are Endolabs Healthcare Pvt. Ltd, Endolabs LifeSciences Ltd, Endolabs Ltdand Spachem Laboratories Ltd.The first three are part of the Indore-based Endolabs pharma marketing group.
The injunction temporarily restrains these companies from using brand names similar to Esgipyrin for marketing the same drug combination .
The court’s interim order passed on April 9, said the brand names —Easypyrin,Elgipyrin,Zypyrineand Agepyrine—are “deceptively similar to that of the original product.”
Piramal said its brand has been in use since 1974. Esgipyrin is currently the brand leader in the Rs300 crore domestic market for anti-pain and -fever combinations. Since the court order is ex parte, there will be hearings later, a date for which is yet to be set.
Ramesh Lulla, key promoter of Endolabs, said he had not seen the court order, and was not aware of any counterfeit move by his company.